More foreign drug firms face scrutiny in China: report (Update)

China is reportedly putting more foreign drug firms under scrutiny, state media said Tuesday, days after the conclusion of a police probe into alleged bribery by employees of Britain's GlaxoSmithKline (GSK).

Earlier this month, Chinese authorities ended a nearly one-year probe into GSK, accusing a top British executive of ordering employees to commit bribery and handing the case over to prosecutors.

Health authorities in the eastern city of Hangzhou were looking into the business practices of other drug companies, including US-based Eli Lilly, Britain's AstraZeneca and Novo Nordisk of Denmark, the 21st Century Business Herald newspaper reported, citing an internal document.

But two of the foreign companies named said the Hangzhou health bureau had not notified them of any such moves.

Another company, Swiss pharmaceuticals giant Roche, has previously said that officials from China's State Administration for Industry and Commerce had visited its offices in Hangzhou. Roche was not cited by the newspaper.

The GSK case came to light in June last year through a local investigation, after police in the central Chinese city of Changsha announced they were examining the company's employees for "economic crimes".

The 21st Century Business Herald said Eli Lilly, AstraZeneca and Novo Nordisk were required to conduct self inspections for kickbacks and report to local authorities.

But Eli Lilly on Tuesday denied it had been approached by Hangzhou health authorities.

"Lilly has not been contacted by (the) Hangzhou Health Bureau," the company said in a statement provided to AFP. "We fully cooperate with any inquiries we receive from (the) government and its agencies in China."

AstraZeneca offered a similar denial.

"We have not received any official communication on this topic at this time. AZ China cooperates with various Chinese authorities on a regular basis across a wide range of interactions," it said.

Novo Nordisk declined to comment, adding it would make a statement if an issue was deemed to have material impact on the company.

An official of the Hangzhou health bureau said no one was available to comment.

China's healthcare sector is widely considered to be riddled with graft, given the opaque tendering system for drugs and doctors' low salaries.

The government last year launched sweeping probes into alleged malpractice by foreign companies in several sectors, and against the backdrop of an anti-graft campaign backed by President Xi Jinping to root out official corruption.

add to favorites email to friend print save as pdf

Related Stories

China targets Germany's Bayer in drug price probe

Sep 13, 2013

Chinese authorities have visited an office of German pharmaceutical giant Bayer, the company said Friday, making it the latest target in a probe of foreign drug firms over high prices.

Probe-hit GlaxoSmithKline announces profits slump

Apr 30, 2014

GlaxoSmithKline, the British drugs giant facing a series of probes into alleged staff corruption, announced sliding profits on Wednesday, one week after unveiling a group makeover.

China state media raises pressure on Britain's GSK

Sep 03, 2013

Chinese state media increased the pressure on British pharmaceutical giant GlaxoSmithKline (GSK) over a bribery investigation Tuesday, accusing the firm of being responsible rather than individual employees.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments